Table 4 depicts some of these clinical trials, including those that evaluate CAR T cells that target CD171 [94] in patients with NB, clinical trial using novel combinations like 131-I-MIBG and ch14.18/CHO, targeting GD2, GM-CSF, and GD2-CAR NKT cells are also discussed. This evidence concerns the gene CSF2 and neuroblastoma.